Generic Name and Formulations:
Ambenonium chloride 10mg; tabs.
Indications for MYTELASE:
Individualize. Usual range: 5–25mg 3 or 4 times daily. Increase gradually at intervals of 1–2 days. Some patients may require 50–75mg per dose. Increasing dosage above 200mg daily requires supervision by clinician aware of signs and treatment of overdose.
Concomitant atropine, mecamylamine, or any other ganglionic blocking agents.
Monitor closely; narrow margin between first appearance of side effects and serious toxic effects. Asthma. Parkinson's disease. Mechanical intestinal or urinary obstruction. Bradycardia. Cardiac conduction disorders. Elderly. Pregnancy. Nursing mothers: not recommended.
Overdosage (eg, excessive salivation, abdominal cramps, diarrhea, miosis, urinary urgency, sweating, nausea, increase in bronchial and lacrymal secretions, vomiting, muscle cramps, fasciculation of voluntary muscles, generalized malaise, anxiety, vertigo).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib